"Primum non nocere (First, do no harm)". Case report
https://doi.org/10.15829/1728-8800-2023-3625
Abstract
Diastolic myocardial dysfunction is the most important pathogenetic factor in heart failure and makes a significant contribution to hemodynamic disorders, which leads to a significant deterioration in the quality of life and prognosis of patients. This article presents a case of a patient with hypertrophic cardiomyopathy with paroxysmal atrial fibrillation and repeated pulmonary edema due to impaired diastolic function, a significant increase in mitral regurgitation and pulmonary hypertension. Given the ineffectiveness of antiarrhythmic therapy and the predicted failure of catheter ablation of the arrhythmogenic focus, the patient was scheduled for atrioventricular destruction. However, the strategy was revised to optimize the heart failure therapy, against which the tachysystole paroxysmal atrial fibrillation did not recur over the following time.
About the Authors
D. A. Nefedova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
R. P. Myasnikov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
S. A. Beregovskaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
References
1. Chand V. Understanding diastolic dysfunction. JAAPA. 2006; 19(3):37-42. doi:10.1097/01720610-200603000-00006.
2. Deswal A. Diastolic dysfunction and diastolic heart failure: mechanisms and epidemiology. Curr Cardiol Rep. 2005;7(3):178-83. doi:10.1007/s11886-005-0074-7.
3. Aroor AR, Mummidi S, Lopez-Alvarenga JC, et al. Sacubitril/ valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness. Cardiovasc Diabetol. 2021;20(1):80. doi:10.1186/s12933-021-01270-1.
4. Sung YL, Lin TT, Syu JY, et al. Reverse electromechanical modelling of diastolic dysfunction in spontaneous hypertensive rat after sacubitril/valsartan therapy. ESC Heart Fail. 2020;7(6):4040-50. doi:10.1002/ehf2.13013.
5. Dyck JRB, Sossalla S, Hamdani N, et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17-31. doi:10.1016/j.yjmcc.2022.03.005.
6. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC Cardiovasc Imaging. 2021;14(2):393-407. doi:10.1016/j.jcmg.2020.07.042.
Review
For citations:
Nefedova D.A., Myasnikov R.P., Beregovskaya S.A. "Primum non nocere (First, do no harm)". Case report. Cardiovascular Therapy and Prevention. 2023;22(7S):3625. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3625
Views:
667
Email this article 
